Acrocyanosis induced by interferon α2a

被引：21

作者：

Campo-Voegeli, A

Estrach, T

Marti, RM

Corominas, N

Tuset, M

Mascaró, JM

机构：

[1] Hosp Clin & Prov Barcelona, Dept Dermatol, E-08036 Barcelona, Spain

[2] Hosp Clin & Prov Barcelona, Dept Pharm, E-08036 Barcelona, Spain

来源：

DERMATOLOGY | 1998年 / 196卷 / 03期

关键词：

interferon alpha(2a); acrocyanosis; long-term side effect; antinuclear antibodies;

D O I：

10.1159/000017917

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

A 56-year-old woman with mycosis fungoides developed acrocyanosis each time treatment with interferon alpha(2a) was started. Acrocyanosis disappeared after discontinuing therapy. Immunological study performed while acrocyanosis was present showed elevated antinuclear antibody (ANA) titers and circulating immune-complex levels. Long-term interferon treatment has been related to autoimmune side effects. Raynaud's phenomenon has been observed in patients undergoing interferon treatment associated with elevated ANA titers, to cryoglobulinemia or to arterial occlusion. Acrocyanosis has never before been described as side effect in patients undergoing this treatment. We believe that our patient's acrocyanosis must be considered a side effect of interferon.

引用

页码：361 / 363

页数：3

共 22 条

[1] ALPHA-INTERFERON AND IMMUNE HEMOLYTIC-ANEMIA
AKARD, LP
HOFFMAN, R
ELIAS, L
SAIERS, JH
[J]. ANNALS OF INTERNAL MEDICINE, 1986, 105 (02) : 306 - 306
[2] Raynaud's phenomenon and digital necrosis induced by interferon-alpha
Bachmeyer, C
Farge, D
Gluckman, E
Miclea, JM
Aractingi, S
[J]. BRITISH JOURNAL OF DERMATOLOGY, 1996, 135 (03) : 481 - 483
[3] BLAHETA RA, 1994, IMMUNOLOGY, V81, P538
[4] RECOMBINANT LEUKOCYTE A-INTERFERON - AN ACTIVE AGENT IN ADVANCED CUTANEOUS T-CELL LYMPHOMAS
BUNN, PA
FOON, KA
IHDE, DC
LONGO, DL
EDDY, J
WINKLER, CF
VEACH, SR
ZEFFREN, J
SHERWIN, S
OLDHAM, R
[J]. ANNALS OF INTERNAL MEDICINE, 1984, 101 (04) : 484 - 487
[5] THYROID AUTOIMMUNITY IN PATIENTS ON LONG-TERM THERAPY WITH LEUKOCYTE-DERIVED INTERFERON
BURMAN, P
TOTTERMAN, TH
OBERG, K
KARLSSON, FA
[J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1986, 63 (05) : 1086 - 1090
[6] INTERFERON-ALPHA AND INTERLEUKIN-2 SYNERGISTICALLY ENHANCE BASIC FIBROBLAST GROWTH-FACTOR SYNTHESIS AND INDUCE RELEASE, PROMOTING ENDOTHELIAL-CELL GROWTH
COZZOLINO, F
TORCIA, M
LUCIBELLO, M
MORBIDELLI, L
ZICHE, M
PLATT, J
FABIANI, S
BRETT, J
STERN, D
[J]. JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (06) : 2504 - 2512
[7] Severe Raynaud's syndrome associated with interferon therapy - A case history
Creutzig, A
Freund, M
[J]. ANGIOLOGY, 1996, 47 (02) : 185 - 187
[8] The Raynaud phenomenon and interferon therapy
Creutzig, A
Caspary, L
Freund, M
[J]. ANNALS OF INTERNAL MEDICINE, 1996, 125 (05) : 423 - 423
[9] DURVOISIN RC, 1976, LANCET, V2, P204
[10] Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684
Kirkwood, JM
Strawderman, MH
Ernstoff, MS
Smith, TJ
Borden, EC
Blum, RH
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (01) : 7 - 17

← 1 2 3 →